If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rareprimary immunodeficiencyDecision based on ...
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK ...
PALO ALTO, CALIFORNIA / ACCESS Newswire / October 2, 2025 / Bioz, Inc., the leading AI-powered citation platform that helps scientific product suppliers drive validation and sales, is excited to ...
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property PortfolioCommercial Focus Remains on U.S. Market as it Continues to Explore Certain Global ...
HemostOD secures CHF 4.3 million seed extension to advance through pre-IND development and commercial scale production Lausanne, Switzerland — 1st October 2025 – HemostOD, a private Swiss company ...
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025· Details of the Phase 3 ...
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors ...
EG 427 Announces Compelling Initial Topline Clinical Results with EG110A DNA Medicine in Neurogenic Bladder Patients Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at ...
Asabys Partners Integrates Aliath Bioventures Life Sciences Investment Platform in Strategic Move with AltamarCAM· Strategic integration fuels Asabys' goal to build a beyond €1 billion life ...
Accumulus Synergy Appoints Khushboo Sharma as Chief Executive OfficerBURLINGAME, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy today announced that its Board of Directors has appointed ...
VANCOUVER, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in ...
Dutch biotech Leyden Labs has raised a €30 million equity investment from the European Innovation Council (EIC) Fund and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback